当前位置: 首页 > 详情页

The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Beijing Neurosurgical Institute, Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China. [2]Department of Neurosurgery, Beijing Tiantan Hospital affiliated to Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China. [3]Beijing Institute for Brain Disorders Brain Tumor Center, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China. [4]China National Clinical Research Center for Neurological Diseases, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China.
出处:
ISSN:

关键词: Clinical characteristics MEN1 Molecular mechanism mTOR PAM

摘要:
Background: Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear. Methods: We summarized the clinical data of 57 PAM patients and compared with sporadic pituitary adenoma (SPA) and sporadic meningioma (SM). 5 pituitary adenomas of PAM and 5 SPAs were performed ceRNA microarray. qRT-PCR, Western Blot, siMEN1 and rapamycin inhibition experiment were validated for ceRNA microarray. Results: Clinical variable analyses revealed that significant correlations between PAM and female sex as well as older age when compared with SPA and significant correlations between PAM and transitional meningioma as well as older age when compared with SM. Additionally, the characteristics of PAM were significantly different for MEN1 patients. Functional experiments showed lower expression of MEN1 can upregulate mTOR signaling, in accordance with the result of ceRNA microarray. Rapamycin treatment promotes apoptosis in primary pituitary adenoma and meningioma cells of PAM. Conclusions: MEN1 plays an important role in PAM by upregulating mTOR signaling pathway. Rapamycin represents a potential therapeutic strategy for PAM in the future. © 2019 The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
JCR分区:
出版当年[2017]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [2]Department of Neurosurgery, Beijing Tiantan Hospital affiliated to Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China.
通讯作者:
通讯机构: [1]Beijing Neurosurgical Institute, Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China. [2]Department of Neurosurgery, Beijing Tiantan Hospital affiliated to Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China. [3]Beijing Institute for Brain Disorders Brain Tumor Center, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China. [4]China National Clinical Research Center for Neurological Diseases, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院